DDInter364 DDInter1348
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, deb
The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical intervention is required. Orlistat is a lipase inhibitor used in the treatment of obesity that works by inhibiting fat-metabolizing enzymes. It was approved by the FDA for use in combination with a reduced-calorie diet in 1999. This drug is a generally well-tolerated and effective weight-loss aid and is now available in both over-the-counter and prescription preparations, depending on the dosage quantity.
Chlorpropamide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Orlistat
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Decreased appetite
Decreased appetite {u} (Side Effect) is caused by {v} (Compound) Orlistat
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Orlistat
Chlorpropamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tolbutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Orlistat
Chlorpropamide {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) resembles {v} (Disease) obesity
obesity {u} (Disease) is treated by {v} (Compound) Orlistat
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Decreased appetite
Decreased appetite {u} (Side Effect) is caused by {v} (Compound) Ergocalciferol
Ergocalciferol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Orlistat
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Pruritus
Pruritus {u} (Side Effect) is caused by {v} (Compound) Telbivudine
Telbivudine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Orlistat
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Urticaria
Urticaria {u} (Side Effect) is caused by {v} (Compound) Sodium Tetradecyl Sulfate
Sodium Tetradecyl Sulfate {u} (Compound) resembles {v} (Compound) Orlistat
Chlorpropamide {u} (Compound) causes {v} (Side Effect) Drug interaction
Drug interaction {u} (Side Effect) is caused by {v} (Compound) Didanosine
Didanosine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Orlistat
Chlorpropamide {u} (Compound) resembles {v} (Compound) Glimepiride
Glimepiride {u} (Compound) treats {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Orlistat
Chlorpropamide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Orlistat (Compound)
Chlorpropamide (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Orlistat (Compound)
Chlorpropamide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Orlistat
Chlorpropamide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Orlistat
Chlorpropamide (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) resembles obesity (Disease) and obesity (Disease) is treated by Orlistat (Compound)
Chlorpropamide (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Ergocalciferol (Compound) and Ergocalciferol may cause a minor interaction that can limit clinical effects when taken with Orlistat
Chlorpropamide (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Telbivudine (Compound) and Telbivudine may cause a moderate interaction that could exacerbate diseases when taken with Orlistat
Chlorpropamide (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Sodium Tetradecyl Sulfate (Compound) and Sodium Tetradecyl Sulfate (Compound) resembles Orlistat (Compound)
Chlorpropamide (Compound) causes Drug interaction (Side Effect) and Drug interaction (Side Effect) is caused by Didanosine (Compound) and Didanosine may cause a moderate interaction that could exacerbate diseases when taken with Orlistat
Chlorpropamide (Compound) resembles Glimepiride (Compound) and Glimepiride (Compound) treats type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Orlistat (Compound)